Modified cyclodextrins as novel non-viral vectors for neuronal siRNA delivery: focus on Huntington’s disease
dc.check.embargoformat | Not applicable | en |
dc.check.info | No embargo required | en |
dc.check.opt-out | Not applicable | en |
dc.check.reason | No embargo required | en |
dc.check.type | No Embargo Required | |
dc.contributor.advisor | O'Driscoll, Caitríona M. | en |
dc.contributor.advisor | Cryan, John F. | en |
dc.contributor.author | Godinho, Bruno M. D. C. | |
dc.contributor.funder | Science Foundation Ireland | en |
dc.contributor.funder | Irish Drug Delivery Network | en |
dc.date.accessioned | 2014-02-24T16:29:43Z | |
dc.date.available | 2014-02-24T16:29:43Z | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014 | |
dc.description.abstract | Huntington’s Disease (HD) is a rare autosomal dominant neurodegenerative disease caused by the expression of a mutant Huntingtin (muHTT) protein. Therefore, preventing the expression of muHTT by harnessing the specificity of the RNA interference (RNAi) pathway is a key research avenue for developing novel therapies for HD. However, the biggest caveat in the RNAi approach is the delivery of short interfering RNA (siRNAs) to neurons, which are notoriously difficult to transfect. Indeed, despite the great advances in the field of nanotechnology, there remains a great need to develop more effective and less toxic carriers for siRNA delivery to the Central Nervous System (CNS). Thus, the aim of this thesis was to investigate the utility of modified amphiphilic β-cyclodextrins (CDs), oligosaccharide-based molecules, as non-viral vectors for siRNA delivery for HD. Modified CDs were able to bind and complex siRNAs forming nanoparticles capable of delivering siRNAs to ST14A-HTT120Q cells and to human HD fibroblasts, and reducing the expression of the HTT gene in these in vitro models of HD. Moreover, direct administration of CD.siRNA nanoparticles into the R6/2 mouse brain resulted in significant HTT gene expression knockdown and selective alleviation of rotarod motor deficits in this mouse model of HD. In contrast to widely used transfection reagents, CD.siRNA nanoparticles only induced limited cytotoxic and neuroinflammatory responses in multiple brain-derived cell-lines, and also in vivo after single direct injections into the mouse brain. Alternatively, we have also described a PEGylation-based formulation approach to further stabilise CD.siRNA nanoparticles and progress towards a systemic delivery nanosystem. Resulting PEGylated CD.siRNA nanoparticles showed increased stability in physiological saltconditions and, to some extent, reduced protein-induced aggregation. Taken together, the work outlined in this thesis identifies modified CDs as effective, safe and versatile siRNA delivery systems that hold great potential for the treatment of CNS disorders, such as HD. | en |
dc.description.sponsorship | Science Foundation Ireland (07/SRC/B1154) | en |
dc.description.status | Not peer reviewed | en |
dc.description.version | Accepted Version | |
dc.format.mimetype | application/pdf | en |
dc.identifier.citation | Godinho, B. M. D. C. 2014. Modified cyclodextrins as novel non-viral vectors for neuronal siRNA delivery: focus on Huntington’s disease. PhD Thesis, University College Cork. | en |
dc.identifier.endpage | 290 | |
dc.identifier.uri | https://hdl.handle.net/10468/1411 | |
dc.language.iso | en | en |
dc.publisher | University College Cork | en |
dc.rights | © 2014, Bruno M. D. C. Godinho | en |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/ | en |
dc.subject | RNA interference | en |
dc.subject | CNS delivery | en |
dc.subject | Neurodegeneration | en |
dc.subject | Gene therapy | en |
dc.subject | Nanotoxicology | en |
dc.subject | PEGylation | en |
dc.subject | Neuroinflammation | en |
dc.subject | Nanotechnology | en |
dc.subject.lcsh | Huntington's chorea--Gene therapy | en |
dc.subject.lcsh | Drug delivery systems | en |
dc.thesis.opt-out | false | |
dc.title | Modified cyclodextrins as novel non-viral vectors for neuronal siRNA delivery: focus on Huntington’s disease | en |
dc.type | Doctoral thesis | en |
dc.type.qualificationlevel | Doctoral | en |
dc.type.qualificationname | PhD (Medicine and Health) | en |
ucc.workflow.supervisor | j.cryan@ucc.ie |
Files
Original bundle
1 - 2 of 2
Loading...
- Name:
- Godinho BMDC_PhD2014.pdf
- Size:
- 8.41 MB
- Format:
- Adobe Portable Document Format
- Description:
- Full Text E-Thesis
Loading...
- Name:
- Godinho BMDC_Abstract_PhD2014.pdf
- Size:
- 107.52 KB
- Format:
- Adobe Portable Document Format
- Description:
- Abstract
License bundle
1 - 1 of 1
Loading...
- Name:
- license.txt
- Size:
- 5.62 KB
- Format:
- Item-specific license agreed upon to submission
- Description: